

Explanation of Conflict of Interest Disclosure Parts:

Part One: All Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical companies doing business with or proposing to do business with ACNP over past 2 years (Jan. 2011-Present)

Part Two: Income Sources & Equity of \$10,000 or greater

Part Three: Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products or companies doing business with or proposing to do business with ACNP which constitutes more than 5% of personal income (Jan. 2011-Present):

Part Four: Grants from pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products directly, or indirectly through a foundation, university, or any other organization (Jan. 2011-Present)

Part Five: My primary employer is a pharmaceutical/biotech/medical device company.

2012 Program Committee Disclosures

Anissa Abi-Dargham: *Part 1:* Pfizer; Otsuka; Takeda; Sunovion; Shire; Roche; Pierre Favre; *Part 2:* Pierre Favre

William Carlezon: *Part 1:* Referring to 2010-2011: Scientific Advisory Board, Myneurolab.com; Consultant, Concert Pharmaceuticals; Consultant, Lantheus Medical Imaging; Consultant, Transcept Pharmaceuticals, (Spouse) Senior Scientist, EMD Serono; *Part 2:* (Spouse) Senior Scientist, EMD Serono, *Part 3:* (Spouse) Senior Scientist, EMD Serono

Cameron Carter: *Part 1:* GlaxoSmithKline research; *Part 4:* GlaxoSmithKline

Karl Deisseroth: *Part 1:* Co-founder of Circuit Therapeutics

Walter Kaye: *Part 1:* A2 grant; *Part 2:* NCSP Faculty support and NIH grant, Price Foundation grant support; *Part 4:* A2

Richard Keefe: *Part 1:* Abbott, Astellas, Asubio, BiolineRx, BrainCells, Bristol-Myers Squibb, Cypress Bioscience, Eli Lilly, EnVivo, Lundbeck, Merck, NeuroCog Trials, Inc., Pfizer, Roche, Sanofi-Aventis, Shire, Solvay, Sunovion, Takeda, and Wyeth; *Part 2:* Abbott, BiolineRx, Cypress Bioscience, Eli Lilly, EnVivo, Lundbeck, Merck, NeuroCog Trials, Inc., Pfizer, Roche, Shire, Sanofi-Aventis, Sunovion; *Part 3:* NeuroCog Trials, Inc.; *Part 4:* GSK, Novartis, Psychogenics

Henry Kranzler: *Part 1:* Alkermes, Lundbeck, GlaxoSmithKline, Roche, Gilead, ACTIVE group received support from Eli Lilly, Janssen, Schering Plough, Alkermes, Lundbeck, GlaxoSmithKline, Abbott and Johnson and Johnson; *Part 2:* Alkermes, Lundbeck

Kaplana Merchant: *Part 1:* Eli Lilly and Company; *Part 2:* Eli Lilly and Company; *Part 3:* Eli Lilly and Company; *Part 5:* Eli Lilly and Company

Andreas Meyer-Lindenberg: *Part 1:* Astra Zeneca, Servier, F. Hoffmann-La Roche Ltd., Pfizer Pharma GmbH, Janssen-Cilag EMEA, F. Hoffmann-La Roche Ltd., Lilly Deutschland GmbH, Gerson Lehrmann Group (GLG), Pricespective, Elsevier, Alexza Pharmaceuticals Inc., Pfizer Pharma GmbH, Astra Zeneca, Outcome Sciences Inc., Desitin Arzneimittel GmbH, Defined Health, Bristol-Myers Squibb GmbH & Co.KGaA

ACNP 2012 Program Committee Disclosures (continued)

Lisa Monteggia: *Part 1:* Speaker's Bureau: Roche, Lundbeck

John Rubenstein: *Part 1:* Neurona Scientific Board

Akira Sawa: *Part 1:* Research Funding: Astellas, Takeda, Tanabe-Mitsubishi, Dainippon-Sumitomo. Consultant: Pfizer, Asubio, Sucampo, Eli Lilly, Taisho, Amgen. Collaboration: Pfizer, Afraxis, Sanofi-Aventis, Astrazeneca, Johnson and Johnson

Darryle Schoepp: *Part 1:* Employee of Merck and Co., Inc., *Part 2:* Merck and Co., Inc., *Part 3:* Employee of Merck and Co., Inc., *Part 4:* Employee of Merck and Co., Inc.; *Part 5:* Employee of Merck and Co.

David Self: *Part 1:* Associate Editor, Neuroscience Letters, Elsevier, Investor, Noorik Biopharmaceuticals Ltd., Riehen, Switzerland; *Part 2:* Investor, Noorik Biopharmaceuticals Ltd., Riehen, Switzerland

David Sibley: *Part 2:* National Institutes of Health (primary employer), American College of Neuropsychopharmacology (editor), American Society for Pharmacology and Experimental Therapeutics (editor), Corporate Resources, LLC (spouse's company)

Pamela Sklar: *Part 1:* Pfizer

Trisha Suppes: *Part 1:* AstraZeneca, Pfizer Inc., National Institute of Mental Health, Sunovion Pharmaceuticals, Jones and Bartlett (formerly Compact Clinicals); *Part 4:* AstraZeneca, Pfizer Inc., Sunovion Pharmaceuticals

Matthew State: *Part 1:* Scientific Advisory Board for Pfizer, Consultant for SynapDx, *Part 2:* Pfizer, Scientific Advisory Board

Audrey Tyrka: *Part 1:* Medtronic, Neuronetic, NeoSync, Lundbeck; *Part 4:* Medtronic, Neuronetic, NeoSync

Dean Wong: *Part 2:* employed by the Johns Hopkins University, School of Medicine, (spouse) employed by NIA/NIH.; *Part 4:* NIH, Amgen, Avid, Biotie, GE, Intracellular, Johnson and Johnson, Lilly, Lundbeck, Merck, Otsuka, Roche, Sanofi-Aventis

Carlos Zarate: *Part 1:* listed as a co-inventor on a patent application for the use of ketamine and its metabolites in major depression. Dr. Zarate has assigned his rights in the patent to the U.S. government but will share a percentage of any royalties that may be received by the government

Program Committee Members with No Disclosures:

Ted Abel	Michael Davidson	Kerry Ressler
Victoria Arango	Jay Gingrich	Etienne Sibille
Aysenil Belger	Paul Kenny	Arielle Stanford
Karen Berman	Thomas Lehner	Daniel Weinberger
Randy Blakely	Arnold Mandell	Rachel Yehuda
Hilary Blumberg	Karoly Mirnics	
Kristin Cadenhead	Bitá Moghaddam	

ACNP 2012 Presenter Disclosures

Bryon Adinoff: *Part 1:* Auxilium Pharmaceuticals, Shook, Hardy & Bacon LLP (medical malpractice consultant, tobacco companies), *Part 2:* Department of Veterans Affairs, UT Southwestern Medical Center

Caleb Adler: *Part 1:* I have participated in multi-site trials including AstraZeneca, Eli Lilly, Pfizer, Otsuka, Forest, Sunovion, Novartis, Glaxo Smith-Kline, and Amylin. I have received research support from AstraZeneca. I have been a speaker and consultant for Merck., *Part 2:* Merck, *Part 3:* Merck, *Part 4:* AstraZeneca

Evdokia Anagnostou: *Part 1:* Consultation fee from SeaSide Therapeutics Consulted without fees to Novartis, *Part 4:* Forest has provided free drug and placebo for a clinical trial

Celso Arango: *Part 1:* Dr. Arango. has been a consultant to or has received honoraria or grants from Astra Zeneca, Bristol-Myers Squibb, Janssen Cilag, Lundbeck, Merck, Otsuka, Pfizer, Roche, Servier and Schering Plough., *Part 4:* Dr. Arango has received grants from Roche and Lundbeck.

Steven Arnold: *Part 1:* Bristol Myers Squibb [advisor board], *Part 4:* Dr. Arnold has received research support from the NIH (R01AG039478, R01AG15819, P30AG10161, P30AG10124, P50MH64045, R01MH075916, R01 DA023210, R01 DA023210, R01 DA025201), the Marian S. Ware Charitable Giving Fund, the Penn Pfizer Alliance, Johnson & Johnson, Neuronetrix, Eli Lilly, American College of Radiology Imaging Network.

David Baker: *Part 1:* Promentis Pharmaceuticals (2010-present), *Part 2:* Promentis Pharmaceuticals (2010-present), *Part 3:* Promentis Pharmaceuticals (2010-present), *Part 4:* Promentis Pharmaceuticals (2010-present)

Deanna Barch: *Part 1:* I have research grants from Novartis and Allon, and I served as a consultant for Pfizer., *Part 4:* Allon and Novartis

Ruth Benca: *Part 1:* Consultant to Merck and Sanofi-aventis.

John Blangero: *Part 4:* Eli Lilly and Co.

Floyd Bloom: *Part 1:* I am a Founder and Director of Alkermes,plc. and as such I am also a shareholder in this publicly traded company., *Part 2:* I am retired. My income sources are from general investments and 401k plans, and from two chairitable remainder trusts., *Part 3:* I am a consultant to Elan Pharma, Inc, as well as a Director of Alkermes,plc. Nither relationship nor any of my other smaller consulting agreements amounts to 5% of my personal income.,

Johannes Bohacek: *Part 4:* Roche (post-doctoral fellowship)

Michael Bogenschutz: *Part 2:* Salary from the University of New Mexico

Christopher Bowie: *Part 1:* I have been a consultant and advisory board member for Abbott Pharmaceuticals from 2010 to present.

Nicholas Brandon: *Part 1:* I am a full time employee of Pfizer, *Part 2:* I am a full time employee of Pfizer, *Part 3:* I am a full time employee of Pfizer

ACNP 2012 Presenter Disclosures (continued)

Edward Bullmore: *Part 1:* GlaxoSmithKline Employee 0.5 FTE, *Part 2:* Income and equity from GlaxoSmithKline, *Part 3:* GlaxoSmithKline Employee 0.5 FTE, *Part 5:* I work half-time for GlaxoSmithKline and half-time for the University of Cambridge

Blynn Bunney: *Part 1:* NeoSync

Ronald Burch: *Part 1:* I am an employee of Naurex, Inc, the Sponsor of the clinical study reported herein., *Part 2:* Naurex, Inc, *Part 3:* Naurex, Inc

Marc Caron: *Part 1:* Lundbeck, Omeros, Roche, Forest Laboratories., *Part 2:* Omeros, *Part 4:* Lundbeck, Roche, Forest Laboratories

William Carpenter: *Part 1:* I have served as a consultant to Lundbeck, Eli Lilly and Company, Bristol-Myers Squibb, Shire Pharmaceuticals, and AstraZeneca

Kiki Chang: *Part 1:* Dr. Chang is a consultant for GSK, Merck, BMS, and Lilly. He receives research funding from GSK and Merck., *Part 4:* GSK, Merck

Charles Chavkin: *Part 1:* Consulting for Trevena 2010-2011, *Part 4:* Contract with Trevena 2010-2011

Alon Chen: See insert

Guang Chen: *Part 1:* Janssen Pharmaceutical Companies of Johnson and Johnson, *Part 2:* Janssen Pharmaceutical Companies of Johnson and Johnson, *Part 3:* Janssen Pharmaceutical Companies of Johnson and Johnson, *Part 4:* Janssen Pharmaceutical Companies of Johnson and Johnson

David Collier: *Part 1:* David Collier will become an employee of Eli Lilly on April 23rd 2012.

Wilson Compton: *Part 1:* Pfizer, General Electric, *Part 2:* None. No income and equity is less than \$10,000 in total for both entities listed above (General Electric and Pfizer)., *Part 3:* None.

P. Jeffrey Conn: *Part 2:* Consulting fee and licensing income through Vanderbilt University from Karuna Pharmaceuticals Licensing income through Vanderbilt University from Johnson and Johnson, Seaside Therapeutics Own equity that does not generate income in Seaside Therapeutics, Karuna Pharmaceuticals, *Part 4:* Johnson and Johnson, Seaside Therapeutics

Edwin Cook: *Part 1:* Consultation - Seaside Therapeutics - 2010, *Part 4:* Seaside Therapeutics - support for site in a multi-site clinical trial

Christopher Correll: *Part 1:* Dr. Correll has been a consultant and/or advisor to or has received honoraria from: Actelion, Alexza; AstraZeneca, Biotis, Boehringer-Ingelheim, Bristol-Myers Squibb, Cephalon, Desitin, Eli Lilly, GSK, IntraCellular Therapies, Lundbeck, Medavante, Medicure, Medscape, Merck, National Institute of Mental Health, Novartis, Ortho-McNeill/Janssen/J&J, Otsuka, Pfizer, ProPhase, Schering-Plough, Sepracor/Sunovion, Supernus, Takeda, Teva and Vanda. He has received grant support from BMS, Feinstein Institute for Medical Research, Janssen/J&J, National Institute of Mental Health (NIMH), National Alliance for Research in Schizophrenia and Depression (NARSAD),and Otsuka., *Part 2:* AstraZeneca, Bristol-Myers Squibb, GSK, Otsuka, Pfizer, ProPhase., *Part 3:* AstraZeneca, Bristol-Myers Squibb, GSK, Otsuka, Pfizer, ProPhase., *Part 4:* BMS, Janssen/J&J, and Otsuka.

ACNP 2012 Presenter Disclosures (continued)

David Cotter: *Part 1:* honorarium research presentation x1 Lilly

Joseph Coyle: *Part 2:* Abbott Pharmaceutical, *Part 4:* BristolMeyerSquibb

John Csernansky: *Part 1:* Membership on a Data Monitoring Committee for Eli Lilly and Co.

Bruce Cuthbert: *Part 2:* NIMH Salary

Kenneth Davis: *Part 1:* My wife, Bonnie Morrison Davis, MD, is a patent holder on the use patent for galantamine for Alzheimer's disease and dementias that has been licensed to Janssen-Pharma, a subsidiary of Johnson & Johnson. She receives royalty income frm this license., *Part 2:* My wife, Bonnie Morrison Davis, MD, is a patent holder on the use patent for galantamine for Alzheimer's disease and dementias that has been licensed to Janssen-Pharma, a subsidiary of Johnson & Johnson. She receives royalty income frm this license., *Part 3:* My wife, Bonnie Morrison Davis, MD, is a patent holder on the use patent for galantamine for Alzheimer's disease and dementias that has been licensed to Janssen-Pharma, a subsidiary of Johnson & Johnson. She receives royalty income from this license.

Geraldine Dawson: *Part 1:* Professional Advisory Board for Integragen, Inc. from which I receive compensation for scientific advice.

Steven DeKosky: *Part 1:* Helicon Therapeutics Genzyme Merck, *Part 2:* none other than primary employment at the University of Virginia, *Part 4:* Elan Pharmaceuticals Novartis Janssen Forest

Melissa DelBello: *Part 1:* Eli Lilly, Amylin, AstraZeneca, Pfizer, Bristol Myers Squibb, Janssen, Johnson and Johnson, Somerset, Shire, Novartis, *Part 2:* Bristol Myers Squibb, Merck, *Part 3:* Bristol Myers Squibb, *Part 4:* Eli Lilly, Amylin, AstraZeneca, Pfizer, Bristol Myers Squibb, Janssen, Johnson and Johnson, Somerset.

Michael Detke: *Part 1:* MedAvante, Sonkei, Rhine, Columbia, Roche, NIH Pharmanet/i3/ Inventiv (partner), *Part 2:* MedAvante, *Part 3:* MedAvante

Wayne Drevets: *Part 1:* Johnson & Johnson, consultant, Esai, Inc., consultant, Myriad/ Rules Based Medicine, consultant, *Part 2:* Johnson & Johnson

Ronald Duman: *Part 1:* Lundbeck, Lilly, Taisho, Forest, J&J, Bristol Myers Squibb, Pfizer, *Part 4:* Lundbeck, Lilly, Forest, J&J

Elliot Ehrich: *Part 1:* Alkermes plc, Full time employee, *Part 2:* Alkermes plc, Full time employee, *Part 3:* Alkermes plc, Full time employee

Wissam El-Hage: *Part 1:* WEH acted as a speaker or consultant for AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co., Janssen, Lundbeck, and Servier France.

Mary-Anne Enoch: *Part 2:* Government salary, two homes, one car

Cagla Eroglu: *Part 4:* Mazorx Inc provided a grant that supported our efforts to find activity blocking antibodies against TSPs.

ACNP 2012 Presenter Disclosures (continued)

Amit Etkin: *Part 4:* Grant from Brain Resource, Inc. for taking part in the International Study to Predict Optimized Treatment in Depression (iSPOT-D)

A. Eden Evins: *Part 1:* Pfizer, GSK, Envivo Pharmaceuticals, *Part 4:* Pfizer, GSK, Envivo Pharmaceuticals

Peter Falkai: *Part 1:* Until the end of 2010 I have been giving paid lectures and was on the advisory boards of the following pharmaceutical companies: Lilly, Servier, AstraZeneca, Janssen-Cilag, Pfizer and Lundbeck., *Part 2:* 20.000 US dollars., *Part 3:* No financial involvement of this amount., *Part 4:* I am currently having a grant from Servier.

Ellen Frank: *Part 1:* Servier International (Consultant) Vanda Pharmaceuticals (Consultant) Guilford Press and American Psychological Association Publishing (Royalties), *Part 2:* Servier International (Consultant) Spouse: Consultant to the American Psychiatric Association

Alan Frazer: *Part 1:* Lundbeck Takeda Lilly Cyberonics, *Part 4:* Lundbeck

Marlene Freeman: *Part 1:* Investigator-Initiated Trials (grants to MGH): Forest, Lilly, GlaxoSmithKline; 1 day advisory board: Bristol Myers Squibb, *Part 2:* Journal of Clinical Psychiatry, *Part 4:* Investigator-Initiated Trials (grants to MGH): Forest, Lilly, GlaxoSmithKline; 1 day advisory board: Bristol Myers Squibb

Jeffrey Friedman: *Part 1:* Envoy Therapeutics, Bay City Capital, Anglian Pharmaceutical, *Part 2:* Envoy Therapeutics, Bay City Capital, Anglian Pharmaceutical

Daniel Geschwind: *Part 1:* Synapdx -- scientific advisory board/consultant Roche -- ad hoc advisory board., *Part 2:* Synapdx 2011-2012

Donald Goff: *Part 1:* In the past 2 years Dr. Goff has received honoraria for consulting or speaking from Hoffman-La Roche, Eli Lilly, Takeda, Dainippon Sumitomo, Endo Pharmaceuticals, Janssen, Cypress Bioscience, Bristol Myer Squibb, Abbott Laboratories and served on a DMC for Otsuka., *Part 4:* Dr. Goff received research funding from Pfizer, GlaxoSmithKline, Janssen, Novartis and PamLab

David Goldman: *Part 2:* NIH - salary Elsevier - book contract American Century - Mutual Fund Thrift Savings Plan - IRA Home Car

Anthony Grace: *Part 1:* Johnson & Johnson, Lundbeck, Pfizer, GSK, Puretech Ventures, Merck, Takeda, Dainippon Sumitomo, Otsuka, Lilly, Roche, *Part 2:* Johnson & Johnson, *Part 3:* Johnson & Johnson, *Part 4:* Lundbeck, GSK, Lilly

Guy Griebel: *Part 1:* Employee of Sanofi.

Roland Griffiths: *Part 1:* Heffter Research Institute - Member of Board of Directors - 2 grants for clinical trials with psilocybin Transcept Pharmaceutical - consulting Alexza Pharmaceuticals - grant for clinical trial Bristol-Myers Squibb - consulting Merck and Co - consulting Vanda Pharmaceuticals - consulting, *Part 4:* Alexza Pharmaceutical --A grant was provided to Johns Hopkins to conduct an abuse liability evaluation with a novel drug delivery system Heffter Research Institute -- Two grants to conduct clinical trials with psilocybin

ACNP 2012 Presenter Disclosures (continued)

Dimitri Grigoriadis: *Part 1:* I am a full time employee of Neurocrine Biosciences Inc., *Part 2:* Salary and Equity associated with full time employment at Neurocrine Biosciences Inc., *Part 3:* I am a full time employee of Neurocrine Biosciences Inc.

Ruben Gur: *Part 2:* Defender's association and Federal and State courts (detailed in my disclosure to the University), *Part 4:* Investigator-initiated grants from Pfizer and AstraZeneca

Jan-Ake Gustafsson: *Part 1:* Consultant for KaroBio AB., *Part 2:* Consultancy fee from KaroBio AB., *Part 3:* No., *Part 4:* No.

Suzanne Haber: *Part 1:* Pfizer

Chang-Gyu Hahn: *Part 4:* Pfizer Pharmaceuticals

Paul Harrison: *Part 1:* Honoraria for scientific talks: AstraZeneca, Otsuka, Takeda Advisory board: Merck, *Part 2:* University of Oxford, *Part 4:* Unrestricted educational grant from Takeda (Cambridge, UK) to the Department of Psychiatry, University of Oxford

Markus Heilig: *Part 2:* none other than primary employment by the US Federal Government

W. Joseph Herring: *Part 1:* Presenter is an employee of Merck., *Part 2:* Merck, *Part 3:* Merck

Ian Hickie: *Part 1:* Paid Educational Seminars/Resources Servier Astra Zeneca Pfizer Eli-Lilly Travel Support from Pharmaceutical or Business Companies Servier Astra Zeneca Price Waterhouse Cooper Research Support from Pharmaceutical Companies: Servier Pfizer, *Part 2:* Professor of Psychiatry, University of Sydney Executive Director, Brain & Mind Research Institute, University of Sydney Clinical Consultant in Psychiatry, Sydney Local Health District (NSW Government Services) Bupa Australia (Private Health Insurance) - Member of the Medical Advisory Panel Headspace: the National Youth Mental Health Foundation- Director on behalf of the University of Sydney, which is a member of the Company.(ENDED JAN 2012, *Part 4:* Hickie I. (2011-2012) Project: Does circadian disturbance predict response to sleep-wake interventions in early-onset depression. Servier, \$100,000.

Florian Holsboer: *Part 1:* Cofounder of HMNC GmbH (Biotech Company) Cofounder and shareholder of Affectis AG (Biotech Company)

Steven Hyman: *Part 1:* Novartis Science Board, *Part 2:* Novartis Fidelity Biosciences (Venture) Access BridgeGap (Venture)

Iliyian Ivanov: *Part 1:* Memeber of Data Safety Monitoring Board for Lundbeck., *Part 4:* Co-investigator on a neuroimaghg grant from Shire awarded to Dr Jeffrey Newcorn at Mont Sinai School of Medicine.

Daniel Javitt: *Part 1:* Solvay, Sepracor, AstraZeneca, Pfizer, Cypress, Merck, Sunovion, Lilly, BMS, Takeda, Glytech, AASI, Promentis, *Part 2:* Pfizer, Glytech, *Part 3:* Glytech, *Part 4:* Pfizer, Roche,

Jarcho Johanna: *Part 2:* National Institute of Health postdoctoral fellowship stipend

Rene Kahn: *Part 1:* AstraZeneca, BMS, Lilly, Otsuka, Roch, Sunovion

ACNP 2012 Presenter Disclosures (continued)

Ned Kalin: *Part 1:* Neuronetics CeNeRx BioPharma Concept Therapeutics CME Outfitters Elsevier, *Part 2:* Elsevier, *Part 3:* Not applicable, *Part 4:* APIRE/Janssen Resident Psychiatric Mentor Grant National Institute of Mental Health The Stanley Medical Research Institute

Peter Kalivas: *Part 2:* Medical University of South Carolina Medical University Associates

Shitij Kapur: *Part 1:* Has served as a one-off consultant and/or speaker for AstraZeneca, Bioline, Bristol Meyers Squibb, Eli Lilly, Envivo, Janssen - Johnson and Johnson, NeuroSearch, Otsuka, Pfizer, Sanofi-Aventis, Schering-Plough, Servier, Solvay Wyeth and serves on the Scientific Advisory Boards for Lundbeck and Roche., *Part 4:* GSK, Lundbeck.

Richard Keefe: *Part 1:* Abbott, Amgen, Astellas, Asubio, Boehringer-Ingelheim, BiolineRx, Bristol-Myers Squibb, Eli Lilly, EnVivo, Helicon, Lundbeck, Merck, Mitsubishi, Novartis, Otsuka, Pfizer, Roche, Shire, Sunovion, Takeda, Targacept, *Part 2:* Abbott, Amgen, BiolineRx, Eli Lilly, EnVivo, Lundbeck, Mitsubishi, Pfizer, Roche, Shire, Sunovion, Takeda, Targacept, *Part 3:* NeuroCog Trials, Inc., *Part 4:* GSK, Novartis, PsychoGenics, Sunovion

Matcheri Keshavan: *Part 1:* I have received two grants, one from Sunovion and another from GSK, in the last two years., *Part 4:* I have received two grants, one from Sunovion and another from GSK, in the last two years.

Thomas Kilduff: *Part 1:* Since I am not a member of ACNP, I have no idea what “companies doing business with or proposing to do business with ACNP over past 2 years.”, *Part 4:* CHDI EMD Serono Research Institute F. Hoffman-La Roche, Ltd. Sunovion

Michael Kilgard: *Part 1:* I am a consultant for and have a financial interest in MicroTransponder, Inc., *Part 2:* I am a consultant for MicroTransponder, Inc., *Part 3:* I am a consultant for MicroTransponder, Inc., *Part 4:* I have a sub-contract from MicroTransponder, Inc. to conduct research that is supported in part by the NIH.

Lori Knackstedt: *Part 2:* MUSC

Scott Kollins: *Part 1:* Research Support: Rhodes Pharmaceuticals, Shire Pharmaceuticals, Otsuka Pharmaceuticals, Addrenex/Shionogi Pharmaceuticals Consultant/Advisory Board: Shire Pharmaceuticals, Otsuka Pharmaceuticals, Addrenex/Shionogi Pharmaceuticals, WebMD/Medscape, *Part 2:* Shire Pharmaceuticals, Otsuka Pharmaceuticals, *Part 4:* Shire Pharmaceuticals

George Koob: *Part 1:* Addes, Alkermes, Arkeo, Embera, Psychogenics

Andrew Krystal: *Part 1:* Abbott, Astellas, AstraZeneca, BMS, Cephalon, Eisai, Eli Lilly, GlaxoSmithKline, Jazz, Johnson and Johnson, MECTA Corp, Merck, Neurocrine, Novartis, Ortho-McNeil-Janssen, Respironics, Roche, Sanofi-Aventis, Somnus, Sunovion/Sepracor, Somaxon, Takeda, Transept, Kingsdown Inc., *Part 4:* NIH, Cephalon, Pfizer, Sunovion/Sepracor, Takeda, Transept, Phillips-Respironics, Astellas, Abbott, Neosynch, Brainsway.

David Kupfer : *Part 2:* University of Pittsburgh American Psychiatric Association

ACNP 2012 Presenter Disclosures (continued)

Steven Kymes: *Part 1:* I am a consultant and receive (or have received) research funding for Pfizer, Bayer and Genentech., *Part 2:* Consulting fees from Bayer in excess of \$10,000 in 2011 and 2012, *Part 4:* As noted above, Pfizer and Genenech in 2010 and 2011.

Paul Lombroso: *Part 1:* President, STEP Solutions, New Haven, CT, *Part 2:* \$0

Dan Lubman: *Part 1:* Honorarium for lectures (AstraZeneca, Janssen)

Angus MacDonald: *Part 2:* University of Minnesota

Robert Malenka: *Part 1:* Circuit Therapeutics, Inc. SAB member

Craig Mallinckrodt: *Part 1:* Employee of Eli Lilly and Co, *Part 2:* Employee of Eli Lilly and CO, *Part 3:* Employee of Eli Lilly and Co

Husseini K. Manji: *Part 1:* Husseini Manji is a full time salaried employee of Johnson & Johnson, *Part 2:* Husseini Manji is a full time salaried employee of Johnson & Johnson, *Part 3:* Husseini Manji is a full time salaried employee of Johnson & Johnson, *Part 4:* Husseini Manji is a full time salaried employee of Johnson & Johnson

Stephen Marder: *Part 1:* Consultant: Abbott, Amgen, Targacept, Lundbeck, Pfizer, Roche, Bristol Meyers Squibb, Otsuka., *Part 4:* Research Support: Novartis, GSK, Sunovion, Psychogenics

Barbara Mason: *Part 1:* SAB: Addex Pharmaceuticals, Lohocla Research Corporation; Consultant: Johnson & Johnson Pharmaceutical Research & Development, LLC, Lilly USA, LLC; Speaker: Merck KGaA

Colleen McClung: *Part 1:* I have received honoraria from Johnson & Johnson, Servier, and Pfizer, *Part 4:* We received research funding from GlaxoSmithKline and Pfizer

James Meador-Woodruff: *Part 2:* Primary employer University of Alabama School of Medicine and University of Alabama Health Services Foundation; ACNP provides an honorarium for service as Editor in Chief of Neuropsychopharmacology, *Part 4:* American Foundation for Suicide Prevention and Ortho-McNeil. Served as PI on an Investigator Initiated project (jointly funded by both) for three month transition between original and current PIs.

Lin Mei: *Part 1:* SAB member, Mind-NRG

Kalpana Merchant: *Part 1:* I am an employee of Eli Lilly and company, a major pharmaceutical company., *Part 2:* As an employee of Eli Lilly and company, I receive income and equity from the company., *Part 3:* I am an employee of Eli Lilly and company, a major pharmaceutical company.

ACNP 2012 Presenter Disclosures (continued)

Jeffrey Meyer: *Part 1:* The author has been a consultant for companies that make antidepressants, including Eli Lilly, SK Life Sciences, Lundbeck, Takeda, Bristol-Myers Squibb, and GlaxoSmithKline, and has received operating grants from some of these companies. It is likely that he will in the future receive consulting contracts or operating grants from companies that make MAO-A inhibitors. He has applied for a patent to use MAO-A measures to predict the course of illness and to treat major depressive disorder., *Part 2:* The author has been a consultant for companies that make antidepressants, including Eli Lilly, SK Life Sciences, Lundbeck, Takeda, Bristol-Myers Squibb, and GlaxoSmithKline, and has received operating grants from some of these companies., *Part 4:* The author has been a consultant for companies that make antidepressants, including Eli Lilly, SK Life Sciences, Lundbeck, Takeda, Bristol-Myers Squibb, and GlaxoSmithKline, and has received operating grants from some of these companies.

David Michelson: *Part 1:* Employee of Merck and Co., *Part 2:* Merck salary and stock, *Part 3:* Merck employee

Emmanuel Mignot: *Part 1:* Novo Nordisk - consulting Jazz Pharmaceuticals - consulting GSK - Advisory Board

Jennifer Mitchell: *Part 1:* I am a founding member of a company that will eventually provide ex vivo GPCR screening.

Lisa Monteggia: *Part 1:* Speaker for Roche and Sepracor

Elaine Morrato: *Part 1:* I have received research grant funding through my university from Janssen Pharmaceuticals, Inc., *Part 4:* I have received research grant funding through my university from Janssen Pharmaceuticals, Inc (2012).

John Morrison: *Part 2:* I have developed monoclonal antibodies that are sold as research reagents that generate royalties in excess of \$10,000 per year.

Charles Nemeroff: *Part 1:* Research/Grants: National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ) Speakers Bureau: None Consulting: Xhale, Takeda, SK Pharma, Shire, Roche, Lilly Stockholder: CeNeRx BioPharma, PharmaNeuroBoost, Revaax Pharma, Xhale, NovaDel Pharma Other Financial Interests: CeNeRx BioPharma, PharmaNeuroBoost Patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1) Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2) Scientific Advisory Boards: American Foundation for Suicide Prevention (AFSP), CeNeRx BioPharma, National Alliance for Research on Schizophrenia and Depression (NARSAD), Xhale, PharmaNeuroBoost, Anxiety Disorders Association of America (ADAA), Skyland Trail, AstraZeneca Pharmaceuticals (2009) Board of Directors: AFSP, Mt. Cook Pharma (2010), NovaDel (2011), Skyland Trail, Gratitude America Income sources or equity of \$10,000 or more: AstraZeneca Pharmaceuticals (2009), PharmaNeuroBoost, CeNeRx BioPharma, NovaDel Pharma, Reevax Pharma, American Psychiatric Publishing, Xhale, *Part 2:* Income sources or equity of \$10,000 or more: AstraZeneca Pharmaceuticals (2009), PharmaNeuroBoost, CeNeRx BioPharma, NovaDel Pharma, Reevax Pharma, American Psychiatric Publishing, Xhale

ACNP 2012 Presenter Disclosures (continued)

Eric Nestler: *Part 1:* PsychoGenics, SAB chair Merck, Consultant Berg Pharma, Consultant, *Part 2:* PsychoGenics, SAB chair Merck, Consultant Berg Pharma, Consultant

John Newcomer: *Part 1:* AstraZeneca Pharmaceuticals Bristol-Myers Squibb BioVail H. Lundbeck Obecure Otsuka Pharmaceuticals Sepracor, Inc. Solvay Pharma, Inc. Teva Pharmaceutical Dainippon Sumitomo Pharma America, Inc. Organon Pharmaceuticals USA Inc. Schering-Plough / Merck Vivus, Inc. Consultant to Litigation Boehringer-Ingelheim, *Part 3:* AstraZeneca Pharmaceuticals Bristol-Myers Squibb BioVail H. Lundbeck Obecure Otsuka Pharmaceuticals Sepracor, Inc. Solvay Pharma, Inc. Teva Pharmaceutical Dainippon Sumitomo Pharma America, Inc. Organon Pharmaceuticals USA Inc. Schering-Plough / Merck Vivus, Inc. Consultant to Litigation Boehringer-Ingelheim, *Part 4:* The National Institute of Mental Health (NIMH) Bristol-Myers Squibb Pfizer, Inc.

Ginger Nicol: *Part 1:* Dr. Nicol has received research funding from the National Institute of Mental Health (NIMH), NARSAD, the Dana Brown Charitable Trust Foundation, the Sidney R. Baer, Jr. Foundation, and the CHADS Coalition for Mental Health. She also receives grant support from Pfizer, Inc. for an investigator-initiated clinical trial. She receives royalties from Jones & Barlett Learning for development of a pediatric metabolic monitoring form and has consulted to MedScape. She does not participate in speakers' bureaus., *Part 4:* Investigator initiated clinical trial grant support: Pfizer, Inc.

Michael Nitsche: *Part 1:* Advisory Boards: UCB, Eisai, GSK, Starstim

Charles O'Brien: *Part 1:* Alkermes consultant Reckitt consultant Embera consultant, *Part 2:* Alkermes Consultant

Charles O'Brien: *Part 1:* Alkermes-Consultant Embera- Consultant Reckitt-Consultant, *Part 2:* Alkermes- Consultant over 2 years

M. Foster Olive: *Part 1:* April - November 2011 - Principal Investigator of contract work for Gilead Sciences

Alvaro Pascual-Leone: *Part 1:* Neosync vB“ Member of Scientific Advisory Board Starlab vB“ Member of Scientific Board Neuronix vB“ Member of Medical and Scientific Advisory Board Johnson & Johnson, Codman vB“ Member of Medical Advisory Board on Neurological and Neurosurgical Technology Nexstim vB“ Advisory Board Member Novavision vB“ Chair, Advisory Board Member Institut Guttman, Spain - Member, Board of Scientific Advisors *Part 4:* Investigator initiated grants from Neuronix, Nexstim, Neuronetics

Sanjeev Pathak: *Part 1:* AstraZeneca; *Part 2:* AstraZeneca; *Part 3:* AstraZeneca; *Part 5:* AstraZeneca

Mani Pavuluri: *Part 2:* AstraZeneca speaker, *Part 4:* Abbott Laboratories and Janssen Pharmaceuticals supplied placebo and active drug for NIH Funded Divalproex vs. Risperdal Double-Blind Placebo Controlled Trial.

Katharine Phillips: *Part 1:* Forest Laboratories (medication only for an NIMH-funded study) Transcept Pharmaceuticals (research funding) Oxford University Press (royalties) Guilford Publications and The Free Press (potential royalties) Elsevier (future honorarium), *Part 2:* NIMH, FDA, Rhode Island Hospital, Alpert Medical School of Brown University, *Part 4:* Forest Laboratories (medication only for an NIMH-funded study) Transcept Pharmaceuticals (research funding)

ACNP 2012 Presenter Disclosures (continued)

Daniel Pine: *Part 2:* Clinical Practice; Editor, American Journal of Psychiatry; NIMH Researcher

William Potter: *Part 1:* Consultant to: AgeneBio, Amgen, Astellas, BMS, EnVivo, Envoy, Index Ventures, J&J, MedAvante, Orasi, Otsuka, Pfizer, Sonkei, Takeda, Theravance, *Part 2:* Merck and Eli LillyStock, *Part 3:* Merck in 2010

Joseph Price: *Part 2:* Faculty salary from Washington University in St. Louis

Eugenii Rabiner: *Part 1:* Until October 2011, was a full time employee of GlaxoSmithKline. I am currently a consultant for GlaxoSmithKline, Biotie and Takeda., *Part 2:* Full time employee of GlaxoSmithKline up to October 2011

Scott Rauch: *Part 1:* UTSW Grand Rounds - Honorarium (2010) Cleveland Clinic Grand Rounds - Honorarium (2010) NIMH Conte Center - OCD Advisory Board - Honorarium (2010) NIMH RDoC - Honorarium (2011) Hall Mercer - Board Member (2010 & 2011) Oxford Univeristy Press - Royalty (2010 & 2011) APPI - Royalty (2010 & 2011), *Part 2:* None other than primary employer: McLean Hospital/Partners Healthcare., *Part 3:* None other than primary employer: McLean Hospital/Partners Healthcare., *Part 4:* Cyberonics Medtronic

Darrel Regier: *Part 4:* Dr. Darrel A. Regier, Director of APIRE and Director of the Division of Research, American Psychiatric Association, oversees all Federal and industry sponsored research and research training grants in APIRE but receives no external salary funding or honoraria from any government or industry sources.

Perry Renshaw: *Part 1:* I am a Consultant and stockholder for Ridge Diagnostics, I am a Consultant for Kyowa Hakko Kirin. I have received royalties on a patent describing the use of uridine to treat bipolar depression from Repligen.

Susan Resnick: *Part 1:* Spouse: Research funding from Amgen, Avid, Biotie, GE, Intracellular, Johnson and Johnson, Lilly, Lundbeck, Merck, Otsuka, Roche, Sanofi-Aventis; Spouse: Consultant Amgen, *Part 4:* Spouse: Research funding Amgen, Avid, Biotie, GE, Intracellular, Johnson and Johnson, Lilly, Lundbeck, Merck, Otsuka, Roche, Sanofi-Aventis

Robert Ring: *Part 1:* I was a full time employee of Pfizer Worldwide Research and Development until May 2011 before joining the non-profit foundation Autism Speaks in my current role., *Part 2:* I was a full time employee of Pfizer Worldwide Research and Development until May 2011 before joining the non-profit foundation Autism Speaks in my current role., *Part 3:* I was a full time employee of Pfizer Worldwide Research and Development until May 2011 before joining the non-profit foundation Autism Speaks in my current role.

Trevor Robbins: *Part 1:* Consultancy: regular: Cambridge Cognition; E. Lilly inc, Lundbeck, GlaxoSmithKline, Merck, Pfizer, ChemPartners Shanghai, Shire Pharmaceuticals. Royalties for CANTAB (Cambridge Cognition), Editing the journal 'Psychopharmacology' (Springer-Verlag), *Part 2:* Cambridge Cognition, Pfizer (2010 only), *Part 3:* Cambridge Cognition, *Part 4:* E. Lilly, Lundbeck, GlaxoSmithKline

Timothy Roberts: *Part 1:* Research Support received from Seaside Therapeutics Consulting, Prism Clinical Imaging, *Part 4:* Research Support received from Seaside Therapeutics

ACNP 2012 Presenter Disclosures (continued)

Bruce Rosen: *Part 1:* Siemens, ABIA (Amyloid Related Imaging Abnormalities, Janssen Scientific, Wolf Greenfield, *Part 2:* Wolf Greenfield

Thomas Roth: *Part 1:* Grants: Apnex, Aventis, Cephalon, GlaxoSmithKline, Merck, Neurocrine, Pfizer, Sanofi, SchoeringPlough, Sepracor, Somaxon, Somnus, Syrex, Takeda, Trancept, Ventus, Wyeth, Xenoport, Consultants: Abbott, Accadia, Acogolix, Acorda, Actelion, Adrenex, Alchemers, Alza, Ance, Arena, AstraZenca, Aventis, AVER, Bayer, BMS, BTG, Cephalon, Cypress, Dove, Eisai, Elan, Eli Lilly, Evotec, Forest, GlaxoSmithKline, Hypnion, Impax, Intec, Intra-Cellular Jazz, Johnson and Johnson, King, Lundbeck, McNeil, MediciNova, Merck, Neurim, Neurocrine, Neurogen, Novadel, Novartis, Ocera, Orexo, Organon, Otsuka, Prestwick, Proctor and Gamble, Pfizer, Purdue, Resteva, Roche, Sanofi, Schoering Plough, Servier, Shire, Somaxon, Somnus, Steady Sleep Rx, Syrex, Takeda, Transcept, Vanda, Ventus, Vivometrics, Wyeth, Yamanuchi, Xenoport, Speakers: Sepracor, Somaxon, *Part 4:* Pfizer, Merck

David Rubinow: *Part 1:* Ad hoc consultant, Pfizer Pharmaceuticals, *Part 2:* Editorial Board, Dialogues in Clinical Neuroscience

Barbara Sahakian: *Part 1:* Professor Barbara Sahakian consults for Cambridge Cognition. She has consulted for Novartis, Shire, GlaxoSmithKline, Lilly, Boehringer-Ingelheim and Hoffmann-La Roche. She holds a grant funded by Johnson and Johnson. She was on the Medical Research Council Neurosciences and Mental Health Board (2010) and on the Science Co-ordination Team for the Foresight Project on Mental Capital and Wellbeing, 2008 (Office of Science, The Department of Innovation, Universities and Skills,). She was on Panel LS5 for the European Research Council. As an Associate Editor, she also receives an honorarium from the journal Psychological Medicine. Prof. Robbins has consulted for Cambridge Cognition, Lundbeck, Pfizer, and Lilly, and has received research grants from GlaxoSmithKline, Lundbeck and Lilly., *Part 4:* Professor Sahakian holds a grant funded by Johnson and Johnson.

Gerard Sanacora: *Part 1:* Dr. Sanacora has received consulting fees from Abbott Laboratories, AstraZeneca, Avanier Pharmaceuticals, Bristol-Myers Squibb, Evotec, Eli Lilly & Co., Hoffman La-Roche, Novartis, and Novum Pharmaceuticals. In addition Dr. Sanacora is a co-inventor on filed patent application by Yale University (PCTWO06108055A1)., *Part 2:* Eli-Lilly & Co., *Part 4:* Dr. has received additional grant support from AstraZeneca, Bristol-Myers Squibb, Hoffman La-Roche, Merck & Co., and Sunovion.

Alena Savonenko: *Part 1:* Jonson&Jonson, *Part 4:* Jonson&Jonson, MAPP

Akira Sawa: *Part 1:* Research Support: Astellas Pharm., Dainippon Sumitomo, Mitsubishi - Tanabe Pharm., Takeda Consultant: Pfizer, Asubio, Sucampo, Eli Lilly, Taisho Collaboration: Pfizer, Afraxis, Astellas Pharm., Dainippon Sumitomo, Mitsubishi - Tanabe Pharm., Takeda, Sanofis-Avenis

Eric Schadt: *Part 1:* SAB of Pacific Bio Sciences, Berg Pharma, and NuMedii

Alan Schatzberg: *Part 1:* Corcept, PharmaNeuroBoost, Forest, Merck, Neurocrine, Jazz, Xhale, Delpport, Biotie, Envivo, CeNeRx, BrainCells, Sunovian, Eli Lilly, Sanofi-Aventis, Takeda, Neuronetics, Cervel, Velocity, *Part 2:* Corcept, PharmaNeuroBoost, Pfizer, Forest, Merck, Neurocrine, Amnestix, *Part 3:* PharmaNeuroBoost

ACNP 2012 Presenter Disclosures (continued)

Christopher Schmidt: *Part 1:* I am employed by Pfizer, Inc, *Part 2:* Pfizer, Inc, *Part 3:* Pfizer, Inc

Mark Smith: *Part 1:* I am an AstraZeneca employee

Linda Spear: *Part 2:* SUNY Research Foundation; State of New York; TIAA/CREF; Ameriprise Financial; HSBC Bank; SEFCU

Reisa Sperling: *Part 1:* Consulting for Bayer, Biogen-IDEC, Bristol-Myers-Squibb, Eisai, Eli Lilly, Janssen, Pfizer, Roche, *Part 4:* Pfizer, Janssen, Bristol-Myers-Squibb, Medivation

Stephen Stahl: *Part 1:* Advent, Alkermes, Arbor Scientia, Arena, Astra Zeneca, Avanir, Biomarin, Boehringer, Ingelheim, Bristol Myers Squibb, Cenerex, Cypress Bioscience, Dey, Eli Lilly, Forest, GenOmind, J & J, Janssen, Jazz, LaboPharm, Lundbeck, Merck, Neuronetics, Neuroscience Education Institute, Novartis, Noven, ONO, Orexigen, Otsuka, PamLabs, Pfizer, PgxHealth, RCT Logic, Rexahn, Roche, Royalty Pharma, Schering Plough, Sepracor, Servier, Shire, Solvay, Sunovion, Trius, Valeant, Vivus, *Part 2:* Arbor Scientia, Astra Zeneca, Biomarin, Boehringer Ingelheim, Dey, Eli Lilly, Forest, GenOmind, GlaxoSmith Kline, Merck, Neuronetics, Neuroscience Education Institute, Novartis, Orexigen, Otsuka, PamLabs, Pfizer, PGxHealth, Roche, Servier, Sunovion, *Part 4:* Astra Zeneca, Avanir, BioMarin, Cenerex, Dainippon Sumitomo, Dey, Eli Lilly, Forest, GenOmind, Lundbeck, Merck, Neuronetics, Novartis, Otsuka, PamLab, Pfizer, PGX Health, Roche, Schering Plough, Sepracor, Servier, Shire, Sunovion, Torrent, Trovis, Valeant

Thomas Steckler: *Part 1:* Employee of Janssen Research & Development, a division of Janssen Pharmaceutica NV

Murray Stein: *Part 1:* UpToDate: Co-Editor-in-Chief for Psychiatry Content Depression and Anxiety (journal): Deputy Editor, *Part 2:* University of California San Diego VA San Diego Healthcare System UpToDate Depression and Anxiety (journal): Wiley Press

Camilla Stoltenberg: *Part 2:* Norwegian institute of public health (government funded) and University of Bergen (public university, government funded)

Edith Sullivan: *Part 2:* Editor-in-chief, Neuropsychology Review

James Swanson: *Part 1:* Noven and Trancept

Neal Swerdlow: *Part 1:* Summer 2011: 1 day of consulting for Neurocrine, Inc.

Joseph Takahashi: *Part 1:* Co-founder and SAB member of Reset Therapeutics, Inc., *Part 2:* Co-founder and SAB member of Reset Therapeutics, Inc.

Michael Thase: *Part 1:* Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly & Co, Dey Pharma LP, Forest Laboratories, H. Lundbeck A/S, MedAvante Inc, Merck & Co Inc, Neuronetics Inc, Otsuka, Ortho-McNeil Pharmaceuticals, PamLab LLC, Pfizer, PGx Inc, PharmaNeuroboost, Rexahn, Roche Labs, Shire US Inc, Takeda, Transcept Pharmaceuticals, *Part 2:* University of Pennsylvania, *Part 4:* Alkermes, Eli Lilly and Company, Forest Pharmaceuticals, Otsuka Pharmaceuticals, PharmaNeuroboost, Roche Labs

ACNP 2012 Presenter Disclosures (continued)

Kay Tye: *Part 1:* Stanford University has filed for patent protection on a technology invented by myself and Karl Deisseroth. I do not receive research funding, royalties or consultant fees from any company., *Part 2:* Salary from Stanford University and stipend from my post-doctoral NRSA Currently, get salary from MIT, Picower Institute and Brain and Cognitive Sciences Department

Sophia Vinogradov: *Part 1:* Brain Plasticity INstitute, Inc.-- consultant on two NIMH SBIR grants. Genentech-- consultant. Amgen-- consultant. Hoffman-LaRoche-- consultant.

Dean Wong: *Part 2:* Dr. Wong is employed by the Johns Hopkins University, School of Medicine His wife, Dr. Susan Resnick, is employed by NIA/NIH., *Part 4:* In addition to research funding from NIH, Dr. Wong has received funding from: Amgen, Avid, Biotie, GE, Intracellular, Johnson and Johnson, Lilly, Lundbeck, Merck, Otsuka, Roche, Sanofi-Aventis.

Marcelo Wood: *Part 4:* My lab received a Sponsored Research Agreement from Repligen Corp., which supported research and Repligen provided small molecule inhibitors for our research.

Allan Young: *Part 1:* Professional involvement with all leading companies in the field of mood disorders in the last 2 years including: AstraZeneca, Janssen, GSK, Otsuka, BMS, Eli Lilly, Servier, Sanofi, and Brain Cells Inc.

Carlos Zarate: *Part 1:* Dr. Zarate is listed as a co-inventor on a patent application for the use of ketamine and its metabolites in major depression. Dr. Zarate has assigned his rights in the patent to the U.S. government but will share a percentage of any royalties that may be received by the government.

Han-Ting Zhang: *Part 1:* Asubio Pharmaceuticals Cordex Biosolutions Lundbeck Pharmaceuticals, *Part 4:* Lundbeck Pharmaceuticals

Following Faculty Had No Disclosures:

Huda Akil	Judy Cameron	Elizabeth Flandreau
Cristina Alberini	Michael Caplan	Andrew Fox
Gary Aston-Jones	Adam Carter	Sophia Frangou
Tracy Bale	Francisco Xavier Castellanos	Guido Frank
Mark Bear	BiGS Consortium	Thomas Franke
Carrie Bearden	Anis Contractor	Bob Freedman
Jill Becker	William Copeland	Felipe Fregni
Catherine Belzung	Richard Davidson	Rita Fuchs
Francine Benes	Luis de Lecea	Wenbiao Gan
Jennifer Blackford	Etienne de Villers-Sidani	Hugh Garavan
Antonello Bonci	Nancy Diazgranados	John Gilmore
Linda Brady	Theodora Duka	David Glahn
Kristen Brennand	Yogesh Dwivedi	Susan Goebel-Goody
Alan Brown	Howard Eichenbaum	Howard Goldman
William Bunney	Monique Ernst	Jill Goldstein
Katherine Burdick	Kate Fitzgerald	Rita Goldstein

ACNP 2012 Presenter Disclosures (continued)

Following Faculty Had No Disclosures:

Charles Grob	Rachel Marsh	Anne Schaefer
Raquel Gur	Kimberley McAllister	Michael Schoenbaum
Frank Haist	Robert McCullumsmith	Thomas Schulze
Ming-Hu Han	Bruce Mcewen	Barry Setlow
Robert Handa	Jacqueline McGinty	Michael Silver
Shawn Harmon	Kathleen Merikangas	Alan Simmons
Mary Heitzeg	Paul Mermelstein	Rajita Sinha
Derik Hermann	Michael Milham	Dana Small
Matt Hill	Guo-li Ming	Jordan Smoller
Tomas Hokfelt	Christopher Monk	Monsheel Sodhi
Elaine Hsiao	Marisela Morales	Wolfgang Sommer
Yasmin Hurd	Janice Naegele	Dietmar Spengler
Kent Hutchison	Alexander Neumeister	Elliot Stein
Thomas Insel	Jack Nitschke	Garret Stuber
Marcus Ising	Matthew Nock	David Sweatt
Sari Izenwasser	Patricio O'Donnell	Susan Swedo
Carrie Jones	Neelroop Parikshak	Michael Taffe
Atsushi Kamiya	Paul Patterson	Nim Tottenham
John Katzenellenbogen	Surojit Paul	Daniela Tropea
Walter Kaye	Martin Paulus	Kuei Tseng
Joel Kleinman	Godfrey Pearlson	Tim Tully
Ami Klin	Adolf Pfefferbaum	Robert Ursano
Cynthia Kuhn	Mary Phillips	Pierre Vincent
Amanda Law	Daniele Piomelli	Nora Volkow
Ellen Leibenluft	Vijay Ramchandani	James Waltz
Jeff Lichtman	Avi Reichenberg	Daniel Weinberger
Daniel Lightfoot	Kathryn Reissner	Danny Winder
Raye Litten	Emilie Rissman	Catherine Woolley
Monica Luciana	Dorit Ron	Anthony Wynshaw-Boris
Beatriz Luna	Amy Roy	Deborah Yurgelun-Todd
Ken Mackie	Scott Russo	